<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Our Pipeline

Building drug conjugates with multimodal mechanisms of action that provide an impenetrable wall of activity.

Progression towards the clinic by 2025 with a strategy for rapid FIH data acquisition

Programs

Target Validation

Therapeutic Discovery

Preclinical

CO-1008:
Hematologic Tumor

Preclinical

CO-1024:
Solid Tumor

Therapeutic Discovery

CO-1025:
Solid & Hematologic Tumor

Therapeutic Discovery


Various
Solid & Hematologic Tumor

Target Validation

Our Therapeutic Programs

A Franchise of CO-1008 Directed Therapies

 
Patients with Acute Myeloid Leukemia (AML) currently have few therapeutic options that provide a durable response to tumors. Despite considerable progress in treatment for Non-Hodgkins Lymphoma (NHL), a significant population of Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), and B Cell Acute Lymphoblastic Leukemia (B-ALL) tumors are either CD19-negative or relapse as CD19-negative tumors. CO-1008 aims to resolve this unmet medical need of patients diagnosed with Acute Myeloid Leukemia (AML) or Non-Hodgkins Lymphoma (NHL).  
 
2
3-3
4-3
5-1
6-3
CO-1008

CO-1024: 1st in Class of ADCs to Treat Solid Tumors

Despite considerable progress made in the treatment of Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Gastric Cancer, and Pancreatic Cancers with immune therapy, only a fraction of these patients respond with durable responses. CO-1024-directed ADCs offer a new approach to the treatment of these malignancies with a high unmet medical need.
 
large image 1-1
CO-1024_2
CO-1024_3
CO-1024_4
CO-1024_5
CO-1024_6